T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
University of Oxford · Jenner Institute · +7 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
642
total citations
- FWCI
- 13.23
- Percentile
- 100%
- References
- 43
Citations per year
Authors
284Topics & keywords
Topics
Keywords
- Coronavirus disease 2019 (COVID-19)
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
- Antibody
- Virology
- 2019-20 coronavirus outbreak
- Medicine
- Clinical trial
- Antibody response
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- AAstraZeneca
- DODivision of Intramural Research, National Institute of Allergy and Infectious DiseasesAward: HHSN272201400008C
- UHUniversity Hospital Southampton NHS Foundation Trust
- URUK Research and InnovationAward: MC_PC_19055
- CFCoalition for Epidemic Preparedness Innovations
- KTKennedy Trust for Rheumatology Research
- ISInternational Seafood Sustainability Foundation
- NINational Institute for Health and Care ResearchAward: MC_PC_19055
- DODepartment of Health and Social Care
- UOUniversity of Oxford
- CAChinese Academy of Medical SciencesAward: 2018-I2M-2-002
- OUOxford University Hospitals NHS Foundation Trust
- VAVersus Arthritis
- HFHuo Family Foundation
- NINational Institute for Health Research Southampton Biomedical Research Centre
- OHOxford Health NHS Foundation Trust
- MRMedical Research CouncilAwards: MR/L006588/1, MR/T001151/1, MC_UU_00008/11, MR/L018942/1
- EAEngineering and Physical Sciences Research CouncilAwards: EP/R013756/1, EP/R013756/1
- NONIHR Oxford Biomedical Research Centre
- NINational Institute of Allergy and Infectious DiseasesAward: HHSN272201400008C